IQ EQ FUND MANAGEMENT IRELAND Ltd Increases Stake in COMPASS Pathways PLC Sponsored ADR $CMPS

IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 67.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 23,842 shares of the company’s stock after purchasing an additional 9,569 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in COMPASS Pathways were worth $67,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in COMPASS Pathways by 93.6% during the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock valued at $30,000 after buying an additional 5,003 shares during the period. Alps Advisors Inc. lifted its stake in shares of COMPASS Pathways by 19.7% in the 1st quarter. Alps Advisors Inc. now owns 66,231 shares of the company’s stock valued at $189,000 after acquiring an additional 10,899 shares during the last quarter. Cerity Partners LLC purchased a new stake in COMPASS Pathways during the 1st quarter valued at about $29,000. ARK Investment Management LLC grew its position in COMPASS Pathways by 4.0% during the 1st quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company’s stock worth $5,162,000 after acquiring an additional 68,601 shares during the last quarter. Finally, BIT Capital GmbH increased its stake in COMPASS Pathways by 112.9% in the 1st quarter. BIT Capital GmbH now owns 246,320 shares of the company’s stock worth $704,000 after purchasing an additional 130,623 shares during the period. 46.19% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. HC Wainwright dropped their price objective on COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, August 4th. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price target on shares of COMPASS Pathways in a research report on Friday, August 1st. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Finally, BTIG Research upped their price objective on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.00.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $6.33 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82. COMPASS Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $7.09. The firm has a market capitalization of $607.30 million, a PE ratio of -3.44 and a beta of 2.21. The company has a 50-day simple moving average of $5.60 and a two-hundred day simple moving average of $4.55.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, analysts anticipate that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.